Peter Selin - Kancera AB Exec Devel

All Insiders . Sweden . 
Stock . Kancera AB . Stakeholders . Insider . Peter Selin
KAN Stock  SEK 1.06  0.01  0.95%   

Insider

Peter Selin is Exec Devel of Kancera AB
Age 50
Phone46 8 50 12 60 80
Webhttps://www.kancera.com

Kancera AB Management Efficiency

The company has return on total asset (ROA) of (0.2736) % which means that it has lost $0.2736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4732) %, meaning that it generated substantial loss on money invested by shareholders. Kancera AB's management efficiency ratios could be used to measure how well Kancera AB manages its routine affairs as well as how well it operates its assets and liabilities.
Kancera AB has accumulated 442 K in total debt with debt to equity ratio (D/E) of 33.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kancera AB has a current ratio of 2.07, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kancera AB until it has trouble settling it off, either with new capital or with free cash flow. So, Kancera AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kancera AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kancera to invest in growth at high rates of return. When we think about Kancera AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Sylvie RyckebuschBioInvent International AB
N/A
Simon EkbergSpectrumone publ AB
N/A
Dominique TersagoCantargia AB
61
Associate WoldbyeCombigene AB
60
Jan NilssonCombigene AB
74
Stefan MBABioInvent International AB
60
Cecilia HofvanderBioInvent International AB
56
Peter BergdahlSpectrumone publ AB
N/A
RGN MScBioInvent International AB
N/A
Susanne LagerlundCantargia AB
N/A
MarcussCantargia AB
N/A
Pr KokaiaCombigene AB
67
Reagan PanggabeanSpectrumone publ AB
N/A
Kenneth ValbollSpectrumone publ AB
N/A
Peter EkolindCombigene AB
59
Adnan DeronicCantargia AB
N/A
Thoas MDCantargia AB
61
Peter MadsenCantargia AB
N/A
Johanna ChristensenCantargia AB
N/A
Louise AspenbergCombigene AB
47
Karin AgermanCombigene AB
50
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. Kancera AB (KAN) is traded on Stockholm Exchange in Sweden and employs 5 people.

Management Performance

Return On Equity-0.47
Return On Asset-0.27

Kancera AB Leadership Team

Elected by the shareholders, the Kancera AB's board of directors comprises two types of representatives: Kancera AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kancera. The board's role is to monitor Kancera AB's management team and ensure that shareholders' interests are well served. Kancera AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kancera AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Olin, CEO Director
Martin Norin, Chief Officer
Hans Richter, Chief Officer
Peter Selin, Exec Devel
Niclas Brynne, Head Devel
Torbjrn Lundstrm, Chief Officer

Kancera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kancera AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.47
Return On Asset-0.27
Operating Margin(72.39) %
Current Valuation14.76 M
Shares Outstanding79.53 M
Shares Owned By Insiders13.72 %
Shares Owned By Institutions2.86 %
Price To Earning(11.64) X
Price To Book1.44 X
Price To Sales168.19 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kancera Stock Analysis

When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY